secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001104659-26-055264
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma Q1 2026 net loss $6.1M; cash $25.1M; NXP900 Phase 1b data expected summer
--------------------------------------------------------------------------------

- Cash and equivalents $25.1M as of March 31, 2026, down from $31.6M at Dec 31, 2025.
- Net loss $6.1M for Q1 2026 vs $5.3M in Q1 2025, increase driven by R&D and G&A costs.
- R&D expenses $4.1M, up $0.4M YoY; G&A $2.2M, up $0.3M YoY.
- NXP900 Phase 1b clinical program enrolling patients in US; monotherapy and combination arms ongoing.
- Preliminary Phase 1b data readout for NXP900 expected in summer 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/0001104659-26-055264-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465926055264/tm2613389d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-055264

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer